Pharmaceuticals APAC

APAC Influenza Antivirals Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

APAC Influenza Antivirals Market Industry Trends and Forecast to 2034: Segmented by (Drug, Buyer, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

APAC · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $298.7 Mn Placeholder estimate
Estimate 2025 $313.7 Mn 24.2% of the global market
Projected 2034 $486.6 Mn 55.1% Adds $172.9 Mn over 9 forecast years
CAGR 2025–2034 5.0% Faster than 5% of 180 Pharmaceuticals markets here
Key players 5
  • APAC is 24.17% of the global market.
  • Among regions, the largest is North America at $633.6 Mn.
  • Fastest growing: Africa at 5.4% a year.
  • APAC ranks 2nd of 6 by size among regions.

Market size projection

APAC

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$172.9 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Influenza Antivirals Market market size by year, APAC
YearMarket sizeChange that yearSince 2025
2024 (estimate) $298.7 Mn — —
2025 (base) $313.7 Mn +$14.9 Mn —
2026 (forecast) $329.3 Mn +$15.7 Mn +5%
2027 (forecast) $345.8 Mn +$16.5 Mn +10.3%
2028 (forecast) $363.1 Mn +$17.3 Mn +15.8%
2029 (forecast) $381.3 Mn +$18.2 Mn +21.6%
2030 (forecast) $400.3 Mn +$19.1 Mn +27.6%
2031 (forecast) $420.3 Mn +$20.0 Mn +34%
2032 (forecast) $441.4 Mn +$21.0 Mn +40.7%
2033 (forecast) $463.4 Mn +$22.1 Mn +47.7%
2034 (forecast) $486.6 Mn +$23.2 Mn +55.1%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

APAC Influenza Antivirals Market Analysis at a glance
Market size, 2025$313.7 Mn placeholder estimate
Forecast, 2034$486.6 Mn placeholder estimate
Growth (CAGR), 2025–20345.0% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug, buyer and end user (see all)
Key playersRoche, Shionogi, GSK PLC, BioCryst Pharmaceuticals, Cipla Inc. (see all)
Active clinical trials56 in Asia PacificSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The APAC Influenza Antivirals Market Analysis Executive Summary

Influenza antivirals treat flu and shorten illness if started early, and are stockpiled for pandemics.

Key segments of the influenza Antivirals market include drug (Oseltamivir, Baloxavir and Zanamivir) and buyer (Retail, Hospitals and Government Stockpiles).

Bar chart: Asia Pacific Influenza Antivirals market size, 2024–2034, placeholder estimates. $298.7 Mn in 2024, $313.7 Mn in 2025 and $486.6 Mn in 2034, 5.0% CAGR.
Asia Pacific Influenza Antivirals market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

APAC Influenza Antivirals Market Dynamics

Market Growth Drivers

Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the influenza Antivirals market.

Opportunity

New vaccines, rapid tests and public-private funding for neglected diseases give the influenza Antivirals market room to grow, especially in Asia, Africa and Latin America.

Market Restraints

Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the influenza Antivirals market.

Competitive Landscape for Influenza Antivirals Market in APAC

The influenza Antivirals market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Influenza Antivirals Market in APAC

Influenza Antivirals in APAC: rules, payment and research

In some of the countries we cover here, medicines are approved by TGA (Australia)⁠[1], NMPA (China)⁠[2], Drug Office (Hong Kong)⁠[3], CDSCO (India)⁠[4], PMDA (Japan)⁠[5], NPRA (Malaysia)⁠[6], Medsafe (New Zealand)⁠[7], FDA Philippines (Philippines)⁠[8], HSA (Singapore)⁠[9] and Thai FDA (Thailand)⁠[10]. How care is paid for in some of these countries: Medicare and the PBS (Australia)⁠[11], basic medical insurance (China)⁠[12], the Hospital Authority (Hong Kong)⁠[13], Ayushman Bharat PM-JAY (India)⁠[14], public health insurance (Japan)⁠[15], subsidised public care (Malaysia)⁠[16], Pharmac (New Zealand)⁠[17], PhilHealth (Philippines)⁠[18], MediShield Life (Singapore)⁠[19] and the Universal Coverage Scheme (Thailand)⁠[20]. ClinicalTrials.gov lists 56 studies on Influenza Antivirals that are recruiting, active or about to start in APAC.⁠[21]

[1] Therapeutic Goods Administration. Checked 14 Nov 2026.

[2] National Medical Products Administration. Checked 14 Nov 2026.

[3] Drug Office, Department of Health. Checked 14 Nov 2026.

[4] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.

[5] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.

[6] National Pharmaceutical Regulatory Agency. Checked 14 Nov 2026.

[7] Medsafe. Checked 14 Nov 2026.

[8] Food and Drug Administration Philippines. Checked 14 Nov 2026.

[9] Health Sciences Authority. Checked 14 Nov 2026.

[10] Thai Food and Drug Administration. Checked 14 Nov 2026.

[11] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

[12] National Healthcare Security Administration. Checked 14 Nov 2026.

[13] Hospital Authority. Checked 14 Nov 2026.

[14] National Health Authority (PM-JAY). Checked 14 Nov 2026.

[15] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.

[16] Ministry of Health Malaysia. Checked 14 Nov 2026.

[17] Pharmac. Checked 14 Nov 2026.

[18] PhilHealth. Checked 14 Nov 2026.

[19] CPF Board, MediShield Life. Checked 14 Nov 2026.

[20] National Health Security Office. Checked 14 Nov 2026.

[21] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in APAC. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for influenza Antivirals. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in APAC.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Influenza Antivirals right now, from free public sources.

Clinical trials

56 active trials in China, India, Japan, Australia, Hong Kong, Philippines, Singapore, Thailand, Malaysia, New Zealand, Bangladesh, Afghanistan, Indonesia, Myanmar, Nepal and Pakistan

Recruiting, about to start, or running now. Counted across the 16 countries we report on in APAC.

Top trial sponsors (worldwide)

  1. Sanofi 6 active trials on ClinicalTrials.gov (opens in a new tab)
  2. ModernaTX, Inc. 3 active trials on ClinicalTrials.gov (opens in a new tab)
  3. Valenta Pharm JSC 3 active trials on ClinicalTrials.gov (opens in a new tab)
  4. Traws Pharma, Inc. 3 active trials on ClinicalTrials.gov (opens in a new tab)
  5. GSK PLC 3 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Influenza Antivirals in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Influenza Antivirals market in Asia Pacific?
Placeholder estimate: about $313.7 Mn in 2025, rising to about $486.6 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Influenza Antivirals market in Asia Pacific growing?
Placeholder estimate: about 5.0% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Influenza Antivirals market report cover?
The report splits the market by drug (Oseltamivir, Baloxavir, Zanamivir, Peramivir), buyer (Retail, Hospitals, Government Stockpiles) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Influenza Antivirals market?
Key players include Roche, Shionogi, GSK PLC, BioCryst Pharmaceuticals and Cipla Inc..
What is driving the Influenza Antivirals market?
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the influenza Antivirals market.
How many clinical trials on Influenza Antivirals are running in Asia Pacific?
56 studies are recruiting, active or about to start in Asia Pacific, counted across the 16 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
How much research is published on Influenza Antivirals?
PubMed lists 47 papers on Influenza Antivirals added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in APAC

See all

Related on influenza and infectious diseases

See the topic